Which RNA-Targeted Drug Discovery Leaders Attended in 2026?
Discover the companies who joined the 9th RNA-Targeted Drug Discovery & Development Summit 2026. Featuring organisations represented by our speakers and delegates, these companies reflect the diverse ecosystem of biotech pioneers, pharmaceutical innovators, and academic researchers united in accelerating the discovery and development of RNA-targeted therapies.
Attending Companies Included
Arrakis Therapeutics
Astellas Pharma
AstraZeneca
Bayer
Biogen
Broad Institute
CHDI
Chugai Pharmaceuticals
Eli Lilly & Co.
EPICS Therapeutics
Fralin Biomedical Research Institute at VTC
Institut Pasteur
Kissei Pharmaceutical
Mol Horizon
National Center for Advancing Translational Sciences (NCATS)
Nippon Shinyaku Co., Ltd.
Novartis
Pfizer
Prism Biolab
PTC Therapeutics
Remix Therapeutics
Renasis Bio
ReviR Therapeutics
RevoNA
Rgenta Therapeutics
Ribometrix
Ribonaut Therapeutics
Sanofi
Schrodinger Inc
Skyhawk Therapeutics
Syrna Therapeutics
UNC Chapel Hill
University of Colorado Boulder
University of Toronto
University of Wisconsin–Madison
Veritas In Silico
Wayfinder Biosciences
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.